Regulatory justifications: Regulating European medicines to maximise market potential

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The justification for regulating is generally considered to rely on benefitting interested groups. Whereas the traditional view is that regulators act as impartial arbiters balancing competing public and private interests, modern accounts consider regulation to be dominated by single interests, such as those of industry. This article challenges these theories by arguing that regulators are substantively (not just procedurally) motivated to justify their actions according to the goals set for them by the bodies that empower them. In consequence, regulators understand their goals as market-based objectives, prompting them to focus on maximising market potential. This is demonstrated in the context of regulating medicines in Europe, through the European Patent Organisation, the CJEU, and the European Medicines Agency. The analysis identifies that regulating to achieve market benefits is a better predictor of regulatory behaviour, but this behaviour frustrates goal achievement (relating to effective and affordable medicines) and only incidentally enables benefits to accrue to specific groups.
LanguageEnglish
Pages61-99
Number of pages39
JournalLaw, Innovation and Technology
Volume8
Issue number1
Early online date22 Apr 2016
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Bioelectric potentials
Medicine
medicine
market
patent
Industry
Group
regulation
industry

Cite this

@article{c7b8c3d104074a76a1a38cbe82ba44b2,
title = "Regulatory justifications: Regulating European medicines to maximise market potential",
abstract = "The justification for regulating is generally considered to rely on benefitting interested groups. Whereas the traditional view is that regulators act as impartial arbiters balancing competing public and private interests, modern accounts consider regulation to be dominated by single interests, such as those of industry. This article challenges these theories by arguing that regulators are substantively (not just procedurally) motivated to justify their actions according to the goals set for them by the bodies that empower them. In consequence, regulators understand their goals as market-based objectives, prompting them to focus on maximising market potential. This is demonstrated in the context of regulating medicines in Europe, through the European Patent Organisation, the CJEU, and the European Medicines Agency. The analysis identifies that regulating to achieve market benefits is a better predictor of regulatory behaviour, but this behaviour frustrates goal achievement (relating to effective and affordable medicines) and only incidentally enables benefits to accrue to specific groups.",
keywords = "Innovation, Regulatory Theory, Healthcare, Public and Private Interests, Market Authorisation, Administrative Decision-Making, Medicines regulation, Patents",
author = "Amanda Warren-Jones",
year = "2016",
doi = "10.1080/17579961.2016.1161890",
language = "English",
volume = "8",
pages = "61--99",
journal = "Law, Innovation and Technology",
issn = "1757-9961",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Regulatory justifications : Regulating European medicines to maximise market potential. / Warren-Jones, Amanda.

In: Law, Innovation and Technology, Vol. 8, No. 1, 2016, p. 61-99.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulatory justifications

T2 - Law, Innovation and Technology

AU - Warren-Jones, Amanda

PY - 2016

Y1 - 2016

N2 - The justification for regulating is generally considered to rely on benefitting interested groups. Whereas the traditional view is that regulators act as impartial arbiters balancing competing public and private interests, modern accounts consider regulation to be dominated by single interests, such as those of industry. This article challenges these theories by arguing that regulators are substantively (not just procedurally) motivated to justify their actions according to the goals set for them by the bodies that empower them. In consequence, regulators understand their goals as market-based objectives, prompting them to focus on maximising market potential. This is demonstrated in the context of regulating medicines in Europe, through the European Patent Organisation, the CJEU, and the European Medicines Agency. The analysis identifies that regulating to achieve market benefits is a better predictor of regulatory behaviour, but this behaviour frustrates goal achievement (relating to effective and affordable medicines) and only incidentally enables benefits to accrue to specific groups.

AB - The justification for regulating is generally considered to rely on benefitting interested groups. Whereas the traditional view is that regulators act as impartial arbiters balancing competing public and private interests, modern accounts consider regulation to be dominated by single interests, such as those of industry. This article challenges these theories by arguing that regulators are substantively (not just procedurally) motivated to justify their actions according to the goals set for them by the bodies that empower them. In consequence, regulators understand their goals as market-based objectives, prompting them to focus on maximising market potential. This is demonstrated in the context of regulating medicines in Europe, through the European Patent Organisation, the CJEU, and the European Medicines Agency. The analysis identifies that regulating to achieve market benefits is a better predictor of regulatory behaviour, but this behaviour frustrates goal achievement (relating to effective and affordable medicines) and only incidentally enables benefits to accrue to specific groups.

KW - Innovation

KW - Regulatory Theory

KW - Healthcare

KW - Public and Private Interests

KW - Market Authorisation

KW - Administrative Decision-Making

KW - Medicines regulation

KW - Patents

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85025824707&origin=resultslist&sort=plf-f&src=s&st1=Regulatory+Justifications%3a+Regulating+European+Medicines+to+Maximise+Market+Potential&st2=&sid=2cfeb5d61692009ddb141b8f33b67290&sot=b&sdt=b&sl=100&s=TITLE-ABS-KEY%28Regulatory+Justifications%3a+Regulating+European+Medicines+to+Maximise+Market+Potential%29&relpos=0&citeCnt=2&searchTerm=

U2 - 10.1080/17579961.2016.1161890

DO - 10.1080/17579961.2016.1161890

M3 - Article

VL - 8

SP - 61

EP - 99

JO - Law, Innovation and Technology

JF - Law, Innovation and Technology

SN - 1757-9961

IS - 1

ER -